Randomized trial · people

VK2735: up to 14.7% weight loss at 13 weeks in VENTURE

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Every dose of VK2735 in this phase 2 trial led to weight loss over 13 weeks, and gut-related side effects were the main issue, reported less often as treatment went on.

Kind
Randomized trial
Studied in
People
Published
2026
Journal
Obesity (Silver Spring)

What they tested

The team wanted to find which weekly doses of VK2735 lead to weight loss over 13 weeks.

How the study was done

A phase 2, randomized, double-blind, placebo-controlled trial that tested several doses of VK2735, given as a weekly shot under the skin, against placebo (a dummy shot) for 13 weeks. It enrolled adults with obesity, or overweight plus at least 1 weight-related health problem, and did not include people with diabetes.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking VK2735? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average weight loss on VK2735 ranged from 9.2 kg (9.1%) in the 2.5 mg arm to 14.6 kg (14.7%) in the 15 mg arm, while the placebo group lost 1.8 kg (1.7%). Among people on VK2735, 93% (130/140) lost at least 5% of their starting weight, compared with 12% (4/34) on placebo. The most common side effects involved the stomach and gut, and people reported them less often once the dose had been stepped up and held steady.

What it doesn’t show

At 13 weeks, this trial is short and does not show what happens with longer use or after stopping. People with diabetes were not included, and the placebo group was small.

The paper

Bays et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026.

The compound

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking VK2735? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo